Cargando…
Mutant IDH1 regulates the tumor-associated immune system in gliomas
Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 (wtIDH1/2) tumors. Although there are many factors underlying the differences in survival between these two tumor...
Autores principales: | Amankulor, Nduka M., Kim, Youngmi, Arora, Sonali, Kargl, Julia, Szulzewsky, Frank, Hanke, Mark, Margineantu, Daciana H., Rao, Aparna, Bolouri, Hamid, Delrow, Jeff, Hockenbery, David, Houghton, A. McGarry, Holland, Eric C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435890/ https://www.ncbi.nlm.nih.gov/pubmed/28465358 http://dx.doi.org/10.1101/gad.294991.116 |
Ejemplares similares
-
Hsp90 Inhibition Decreases Mitochondrial Protein Turnover
por: Margineantu, Daciana H., et al.
Publicado: (2007) -
The dominant TP53 hotspot mutation in IDH-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications
por: Marker, Daniel F, et al.
Publicado: (2021) -
Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023) -
Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
por: Wollring, Michael M., et al.
Publicado: (2022) -
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)